have also been implicated in the MDR phenotype, although not specifically in rhabdomyosarcoma. LRP sequesters drugs thereby reducing their availability in the cell. P-gp and MRP efflux a variety of drugs used to treat cancer, thereby reducing the availability of drug at the target and reducing the effectiveness of treatment.
Ways of reversing or modulating multidrug resistance have been researched extensively in recent years and several compounds have been found which affect the MDR mechanisms (reviewed by Ford, 1996) . These include the immunosuppressive cyclosporin A and the calcium channel-blocker verapamil. The effectiveness of these agents in rhabdomyosarcoma in vitro has been investigated (Cowie et al, 1998) . However, the use of these agents as MDR modulators in vivo is limited by toxicity due to side-effects such as nephrotoxicity for cyclosporin A and cardiac toxicity for verapamil.
Currently one of the most promising MDR modulators is the non-immunosuppressive cyclosporin A analogue, PSC833, which is specific for P-gp (Naito and Tsuruo, 1997) . This is currently undergoing phase III clinical trials in relapsed acute myeloid leukaemia and in relapsed or refractory multiple myeloma. The compound has also undergone several phase I and II trials in various types of cancer. Another compound is the novel modulator VX710 (Germann et al, 1997a) , a non-macrocyclic pipecolinate derivative which binds the FK506 receptor protein. It inhibits the efflux activity of P-glycoprotein and stimulates vanadate sensitive P-glycoprotein ATPase activity, suggesting a direct high-affinity interaction between VX710 and P-glycoprotein (Germann et al, 1997a) . VX710 has also been shown to modulate MRP-mediated multidrug resistance, possibly by direct interaction (Germann et al, Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines 1997b). This agent is currently in phase II clinical trials in breast cancer, ovarian cancer, soft-tissue sarcoma, liver cancer and prostate cancer.
MDM2 protein binds and inactivates the tumour suppressor protein p53 (Lane, 1992) and has recently been implicated in the development of drug resistance (Kondo et al, 1996) . It is known that mdm2 is often overexpressed in sarcomas and in particular in rhabdomyosarcoma (Keleti et al, 1996) . The study also showed that when mdm2 expression was normal, the tumour suppressor gene, p53, was often mutant. Separate studies have shown that p53 mutations are often present in childhood rhabdomyosarcomas, particularly at relapse (Felix et al, 1992; Wurl et al 1996) .
In the present study a panel of seven paediatric rhabdomyosarcoma cell lines have been characterized with regard to p53, p21 and mdm2 in addition to drug resistance phenotype and sensitivity to the commonly used anti-cancer drugs, cisplatin, doxorubicin, etoposide and vincristine. The ability of two different drug resistance modulators to improve sensitivity has also been investigated.
MATERIALS AND METHODS

Cell lines
The panel of rhabdomyosarcoma cell lines is summarized in Table  1 . Rh18, Rh30 and Rh36 were gifts from Dr PJ Houghton (St Judes Children's Research Hospital). SCMC was a gift from T Sawada (Kyoto Prefectural University of Medicine, Japan). RMS and RD were obtained from the American Tissue Culture Collection (Rockville, Maryland, USA). All the rhabdomyosarcoma lines used are negative for EWS-FLI-1 (Dr A Gordon, personal communication). The lines Rh18, Rh30 and RMS have the PAX3-FKHR translocation associated with t(2;13)(q35;q14) and the line SCMC has a t(9;13) translocation, which does not affect the FKHR gene, in addition to a cryptic der(13)t(2;13)(q35;q14) translocation (Dr A Gordon, personal communication).
The human ovarian carcinoma cell line CH1 and its multidrug resistant variant CHIDoxR were used as negative and positive controls for P-glycoprotein expression and function (Sharp et al, 1994) . The human non-small cell lung carcinoma cell line CORL23 and its multidrug resistant variant CORL23/R were used as negative and positive controls for MRP expression (Barrand et al, 1994) . The non-small cell lung cancer cell line 2R120 and the breast cancer cell line MCF-7 were used as positive and negative controls respectively for LRP expression (Scheper et al, 1993) .
The ovarian cell line A2780 was used as a wild-type p53 control (Pestell et al, 1998) .
All cell lines were maintained in RPMI 1640 medium (Sigma, Poole, Hants, UK) supplemented with 10% foetal bovine serum (Life Technologies, Scotland, UK) and 2 mM L-glutamine (Sigma). Cells were grown as attached monolayers and were incubated at 37°C in a humidified atmosphere with 5% CO 2 . All cell lines were routinely screened for Mycoplasma by PCR assay (Stratagene, Cambridge, UK).
Drugs and chemicals
Vincristine (David Bull Laboratories) and etoposide (Bristol Myers Squibb Pharmaceuticals) stock solutions were obtained as pharmacy preparations at concentrations of 1.083 mM and 34 mM respectively. Doxorubicin (Sigma) was dissolved in water to give a stock solution of 1 mM. Cisplatin (Johnson Matthey Technology Centre, Reading, UK) was dissolved in 0.9% saline to give a stock solution of 1 mM. VX710 (Vertex Pharmaceuticals Inc, Cambridge, MA, USA) was dissolved in saline to give a 50 mM stock solution. Finally, PSC833 (Sandoz Pharmaceuticals, Camberley, UK) was dissolved in absolute ethanol to give a 1 mM stock. All of these drugs were stored at -20°C with the exception of vincristine which was stored at 4°C. Immediately prior to use the drugs were diluted using RPMI 1640 medium prepared as for cell culture, with the exception of vincristine which was diluted in RPMI 1640 medium without any supplements.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) was dissolved in PBS to produce a stock solution of 5 mg ml -1 which was stored at 4°C.
Immunoblotting
Exponentially growing cells were harvested by trypsinization, washed in PBS then incubated in 200-300 µl of lysis buffer (pH 7.5, 150 mM NaCl, 50 mM Tris-HCl, 1 mM phenylmethylsulphonyl fluoride (PMSF), 2 µg ml -1 aprotinin, 2 µg ml -1 leupeptin, 1 mM sodium orthovanadate, 1% NP40 and 0.2% sodium dodecyl sulphate (SDS) at 4°C for 1 h. Cells were then centrifuged at 7000 g (MSE Microcentrifuge) at 4°C for 15 min. The protein-containing supernatant was collected and stored at -70°C. When immunoblotting for P-glycoprotein a membrane protein preparation from the cells was used. Cells were harvested by trypsinization, washed with PBS then lysed in 1 mM Tris (pH 7.4) containing 100 µg ml -1 PMSF at 4°C for 1 h. Nuclei and unbroken cells were removed by centrifugation (450 g, 10 min, 4°C). The resulting supernatant was centrifuged (60 000 g, 1 h, 4°C) to pellet the cell membranes. The membrane proteins were resuspended in lysis buffer and stored at -70°C.
The protein content of the samples was determined using a BCA assay kit (Pierce, Rockford, IL, USA). Cell lysates were then diluted 1:1 in 2× Laemmli buffer (62.5 mM Tris-HCl pH 6.8, 20% (v/v) glycerol, 10% (v/v) β-mercaptoethanol, 5% (w/v) SDS, 0.005% (w/v) bromophenol blue) and denatured for 3 min at 95°C. Proteins were resolved by electrophoresis down an 8-16% SDS-PAGE gradient gel as previously described (Sharp et al, 1995) . When immunoblotting for P-gp or MRP, a 6% gel was used, to ensure better separation of the protein of interest. Equal amounts of protein from each sample were loaded into each well, typically 60 µg.
Proteins were then electroblotted onto a nitrocellulose filter (Millipore) (Towbin et al, 1979) in a transfer buffer containing 10% methanol at 300 mA for 2 h at 4°C. Even loading and transfer of proteins was assessed by staining with Ponceau S. The nitrocellulose filter was then blocked overnight in PBS (pH 7.6) containing 0.5% casein. Target proteins were detected using a primary antibody and an appropriate horseradish peroxidaselabelled secondary antibody followed by enhanced chemiluminescence reagents (Amersham). Exposure of the nitrocellulose filter to film (Hyperfilm-ECL, Amersham) was used to visualize protein bands. The antibodies used were C219 (Centocor, USA) to detect P-gp, MRPm6 (Monosan, Netherlands) to detect MRP, IF-2 (Oncogene, Cambridge, MA, USA) to detect MDM2, C19 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) to detect p21, DO-1 (Santa Cruz Biotechnology) to detect p53 and B-1-5-2 (Sigma) to detect α-tubulin.
Immunohistochemistry
Cytospin preparations of approximately 50 000 cells were fixed in acetone (for MRP and LRP) or 4% paraformaldehyde (P-gp) for 5 min, air-dried and pre-incubated in 10% rabbit serum in TBS. This was followed by incubation with primary antibody for 1 h. The antibodies used were MRK 16 (TCS Biologicals, Botolph Claydon) diluted 1:50 to detect P-gp, MRPm6 diluted 1:100 to detect MRP and LRP 56 (TCS Biologicals) diluted 1:20 to detect LRP. All antibodies were titrated to ensure maximum sensitivity. Incubation with the primary antibody was followed by incubation for 30 min with rabbit anti-mouse antibody (Dako, Glastrup, Denmark) diluted 1:50. A standard APAAP technique (Dako) was used for colourimetric development with levamisole (Sigma) to block activity of endogenous alkaline phosphatase. All incubations were carried out at room temperature. Slides were counterstained with Mayer's haematoxylin (Sigma) for 2 min. Cells were graded as negative (-) when no staining was apparent, positive (+) when staining was clear and unclear (-/+) when staining was difficult to detect. In all cases, appropriately matched isotype controls and no antibody controls were used.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
All sequences of PCR primers were as previously reported. RT-PCR analysis used the following primer sets: mdr-1, 157 bp product (Bordow et al, 1994) , mrp-1, 140 bp product (Bordow et al, 1994) and lrp, 405 bp product (Stein et al, 1997) . All primer sets spanned an intron to control against amplification of genomic DNA sequences. All primers were purchased from Oswel DNA Service Lab (Southampton, UK).
Total RNA (1 µg) was reversed transcribed in a 20 µl volume using Superscript (GIBCO BRL, Scotland, UK) and random hexonucleotides (Pharmacia), according to the manufacturer's instructions. PCR was performed in a final volume of 25 µl containing 0.5 µM of each primer, 0.2 mM dNTPs (Pharmacia), 2.5 U µl -1 Taq DNA Polymerase (GIBCO BRL), Taq buffer (GIBCO BRL) and 1.5-2 mM MgCl 2 (GIBCO BRL). An initial denaturation for 4 min at 94°C was followed by 35 cycles of 30 s at 94°C, 60 s at 55°C and 60 s at 72°C in an Omnigene thermal cycler (Hybaid, UK). PCR products were visualized by electrophoresis using a 1.5% agarose gel and ethidium bromide staining.
p53 functional analysis
To provide some indication of the p53 functional status, induction of P53, P21 and MDM2 was measured following irradiation (O'Connor et al, 1997) . Exponentially growing cells were exposed to 5 Gy irradiation delivered using a 60 Co source with a source-toflask distance of 40 cm and a dose rate of 1.36 Gy min -1 . Cells were incubated for a further 4 h then harvested for protein extraction. The protein extracts were immunoblotted as above then probed for MDM2, P53 and P21. The proteins from irradiated cells were compared with protein from untreated cells to monitor changes in these proteins. The samples were also probed for α-tubulin to ensure even loading.
Growth inhibition assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Mosmann, 1983 ) was used to measure growth inhibition. Cells were added to each well of a flat bottom 96-well microtitre plate (Falcon, Becton Dickinson, Cowley, UK) at concentrations of 2 × 10 3 -1 × 10 4 cells per well. The seeding density was optimized to allow at least three cell doublings during the assay. The cytotoxic agents doxorubicin, vincristine, cisplatin and etoposide were added 24 h later. The cells were then incubated for a further 5 days (7 days for Rh18) after which the number of viable cells was determined using the MTT assay. Each experimental point was set up in quadruplicate wells and repeated on three separate occasions. The number of viable cells surviving drug exposure was expressed as a percentage of the number of viable cells in the absence of drug. This percentage was then plotted against drug concentration and from this the IC 50 (cytotoxic dose at which half the cells survive) was obtained.
The method was slightly modified in order to test the effect of the modulators PSC833 and VX710 on the chemosensitivity of the cell lines. The effects of the modulators alone were tested using an MTT assay similar to that outlined above. From this a concentration of modulator was chosen which killed no more than 10% of the cells in each cell line. This concentration was 2 µM for both modulators. The MTT assays were then carried out as above, except that after 24 h, modulator was added to each well before addition of the drug. The assay was then continued as normal. On each plate controls were included and any cytotoxic effects of the modulators were accounted for in the calculation of IC 50 . The ratio of IC 50 with and without modulator treatment gives the sensitization ratio (SR) which was used to compare modulation between cell lines. These experiments were carried out using the panel of seven rhabdomyosarcoma cell lines and also using CH1 and CH1DoxR as negative and positive controls for modulation. 3 H]-VCR, the cells were aspirated dry, washed with PBS at 4°C, and lysed with 2 ml of 1 N NaOH. Lysis was carried out for 12 h at 37°C then 1.6 ml of lysate was transferred to a scintillation vial, mixed with 10 ml scintillation fluid (Ultima Gold, Packard), and counted for tritium in a liquid scintillation counter (2200CA, Packard). The remaining 0.4 ml was used to determine protein concentration using the Lowry method (Lowry et al, 1951) . From these measurements the accumulation of [ 3 H]-VCR per mg protein was calculated.
Vincristine accumulation assay
RESULTS
Characterization
Expression of three genes implicated in multidrug resistance (mdr-1, mrp-1 and lrp) was assayed at both the protein and mRNA level in the rhabdomyosarcoma cell line panel. Expression of P-gp and MRP proteins was not detectable in the rhabdomyosarcoma cell lines by immunoblotting (Figure 1 ) whereas the control cell lines gave a strong signal. Immunohistochemical staining showed that expression of MDR proteins was undetectable or very low in all of the cell lines except HX170 which has expression of LRP (Table 2A) . In many cases the staining was barely detectable, as illustrated in Figure 2 . Despite the difficulties in detecting proteins, many of the cell lines were found to contain mRNA for the resistance genes (Table 2B) . mdr-1, mrp-1 and lrp were found in 5/7, 7/7 and 5/7 cell lines, respectively. The detection of these is probably due to the high sensitivity of the PCR assay compared to the protein detection methods.
The p53 phenotype of the cell line panel was investigated by measuring levels of P53, P21 and MDM2 4 h following 5 Gy irradiation and comparing these to untreated controls (Figure 3) . The α-tubulin levels vary between cell lines but are consistent within cell-line paired samples, showing that loading was reasonably accurate. The experiment was repeated twice and the blots analysed using ImageQuant software.
In the wild-type control, A2780, there is an increase in expression of MDM2 and P53 leading to a downstream increase in P21, consistent with the presence of functional p53. Of the rhabdomyosarcoma cell lines only one, SCMC, appears to be functionally wild-type for p53. In HX170 an increase in P21 is seen following irradiation but there is no corresponding increase in P53 so it is unclear whether p53 is functional. An increase in P21 levels following irradiation is also seen in RMS, possibly indicating some p53 function. Rh18 and Rh36 showed overexpression of MDM2 leading to high levels of P53 and P21 and no response following irradiation. Both Rh30 and RD had high levels of P53 prior to irradiation and showed no induction of P21, suggesting mutant p53. Overall, there was no clear correlation between drug sensitivity and p53/mdm2 status, although SCMC, which has wild-type p53 and is derived from a heavily treated patient, was relatively sensitive to the DNA-damaging agents cisplatin, etoposide and doxorubicin. The line HX170 exhibits an interesting pattern of drug sensitivity as it is most resistant to doxorubicin and etoposide but relatively sensitive to cisplatin and vincristine.
Modulation of sensitivity
The ability of PSC833 and VX-710 to modulate sensitivity to cisplatin, doxorubicin, etoposide and vincristine was measured ( Figure 5) . A sensitization ratio greater than 1 indicates that modulation is taking place. For cisplatin the sensitization ratios are all approximately 1 ( Figure 5A ). This would be expected because cisplatin is not a substrate for P-gp or MRP. With etoposide ( Figure 5C ) some sensitization is seen in HX170, SCMC, RD and Rh18 but this is low (approximately 2-fold) compared to the sensitization in CH1DoxR (up to 17.8-fold). The amount of sensitization seen in CH1DoxR is greatest with doxorubicin and vincristine Figure 5B and 5D ) and is as much as 455-fold. The sensitization seen in the rhabdomyosarcoma lines is considerably less than this but is as high as 16-fold in SCMC with vincristine. Sensitization is also seen at lower levels in HX170 and RD.
The modulator PSC833 is more potent in modulation of VCR sensitivity in the CH1DoxR ovarian line whereas the modulator VX710 is significantly more potent in the rhabdomyosarcoma lines (paired t-test, P < 0.0001).
The sensitization by the modulators is greatest with vincristine and this may be due to the uptake and efflux mechanisms for this drug. To investigate this, accumulation of 10 nM and 25 nM [ 3 H]-VCR was measured both in the presence and absence of PSC833. PSC833 caused an increase in accumulation in all rhabdomyosarcoma lines from 1.1-fold in Rh36 to 2.2-fold in SCMC (Figure 6) . Interestingly, the greatest increase was seen in SCMC, but this was not statistically significant. The accumulation of [ 3 H]-VCR by CH1DoxR was lower than all the other lines but could be increased up to 15-fold by addition of PSC833.
DISCUSSION
Rhabdomyosarcoma is an important childhood malignancy where drug resistance to the major drugs used to treat the disease (vincristine, etoposide and doxorubicin) limits cure rates. This study reports the characterization of a panel of human cell lines in terms of the major proteins which may influence drug response, chemosensitivity and sensitization by two clinically studied modulators of multidrug resistance.
The rhabdomyosarcoma cell line panel comprises lines derived from both previously untreated and chemotherapy-treated patients and displays a wide variety of phenotypes. There are similar numbers of lines of alveolar and embryonal histology. All of the lines tested negative for P-gp and MRP by immunoblotting although it is likely that this technique is not sensitive enough to identify low levels of the proteins. This is supported by the results of immunohistochemical staining, which suggests that the level of proteins is very low and barely detectable, with the exception of HX170 which expresses LRP.
Consequently, RT-PCR has also been used and shows that the majority of lines have mdr-1, mrp-1 and lrp mRNA. Similar observations have also been made in neuroblastoma (Yanagisawa et al, 1999) . However, the expression of mRNA does not always reflect the expression of the protein.
Our studies of the p53 pathway are based on the model that wild-type p53 induces P21 expression following irradiation and that therefore induction of P21 is indicative of wild-type p53 (O'Connor et al 1997) . However, it should be noted that alternate mechanisms may also be involved and that our observations therefore only provide a suggestion of p53 status.
Clinical observations suggest that the function of p53 is often compromised in paediatric rhabdomyosarcoma (Wurl et al, 1996) . In agreement with this, it is evident from our studies that only one of the seven rhabdomyosarcoma lines, SCMC, shows P21 induction following irradiation, suggesting functional p53. Interestingly, this cell line was relatively sensitive to the DNA-damaging agents cisplatin, etoposide and doxorubicin, and this is in agreement with data using the 60 cell-line NCI panel to correlate p53 status and drug sensitivity (O'Connor et al, 1997) . HX170 also shows some induction of P21 but its status is unclear. Rh30 and RD have mutations in exons 8 and 7 respectively (Felix et al, 1992; Keleti et al, 1996) . Our results suggest that these mutations lead to a loss of p53 function, as illustrated by the lack of P21 induction following irradiation. Two of the lines, Rh18 and Rh36, show overexpression of MDM2, confirming previously published data (Felix et al, 1992; Keleti et al, 1996) . We hypothesize that the overexpression of MDM2 leads to inactivation of P53 and thus no induction of P21 following irradiation. Previously published reports have shown that RMS has a point mutation in the p53 gene (Stratton et al, 1990) . We have observed a slight induction of P21 following irradiation in this line. We therefore propose that this mutation may not disable p53 function completely or may be heterozygous.
Neither the presence of MDR proteins nor p53 status of these lines appeared to correlate with sensitivity to commonly used chemotherapeutic agents. HX170 showed reduced sensitivity to cisplatin, doxorubicin and etoposide but not to vincristine, and SCMC and RD were relatively resistant to vincristine alone. Interestingly, all three lines are derived from heavily treated patients and all three lines show some modulation of sensitivity. Only two of the lines, Rh18 and Rh30, were taken from untreated patients and neither of these showed any modulation. Four of the lines from treated patients showed modulation, as high as 16-fold in SCMC. The level of modulation seen in these lines is relatively low and therefore it is likely that the MDR proteins present are at low levels. This may also be more relevant to clinical levels of expression, where levels of modulation are also low (Cowie et al, 1995) .
Sensitization of the rhabdomyosarcoma lines to vincristine was greater with VX710 than PSC833, in contrast to the P-gpexpressing ovarian line CH1DoxR. This suggests that the rhabdomyosarcoma lines may also have low levels of MRP which is affected by VX710 but to a lesser effect by PSC833 (Germann et al, 1997b) . This is supported by the observation that all the cell lines express mrp1 mRNA ( Table 2) .
The ability of the cells to accumulate radiolabelled vincristine was measured both in the absence and presence of PSC833. In all cell lines PSC833 increased accumulation of vincristine, regardless of MDR phenotype. This implies that there may be low levels of transport proteins in all the cells which are affected by PSC833. Alternatively, PSC833 may act via a different mechanism to increase drug accumulation. One hypothesis is that exposure to drugs activates a stress response pathway which activates P-gp and/or mdr-1 production (Chaudhary and Roninson, 1993) . Therefore the MDR phenotype of the unstressed cell does not reflect the situation when drugs are added and PSC833 may interact with the stress response pathway.
In conclusion, the rhabdomyosarcoma cell lines studied do not show high levels of multidrug resistance. Despite the lack of easily detectable MDR proteins, there is evidence that the proteins are present at very low levels. There is also evidence that the sensitivity of the rhabdomyosarcoma lines to drugs, especially vincristine, can be modulated, by as much as 16-fold in SCMC, and that accumulation of vincristine can also be increased using modulators. This may have clinical implications in terms of excluding P-gp and MRP 'non-expressors' from clinical trials of modulating agents or looking for clear correlations between expression and modulation benefit. These lines provide a good model for the development of new strategies in the treatment of paediatric rhabdomyosarcoma and for elucidating relationships between protein expression and drug resistance.
